Aberdeen Group plc Has $145.53 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Aberdeen Group plc trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,185,676 shares of the biopharmaceutical company’s stock after selling 162,368 shares during the quarter. Aberdeen Group plc’s holdings in Gilead Sciences were worth $145,530,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ameriprise Financial Inc. increased its position in Gilead Sciences by 397.6% in the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after purchasing an additional 5,392,191 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Gilead Sciences by 164.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after buying an additional 2,169,266 shares during the period. First Trust Advisors LP raised its stake in shares of Gilead Sciences by 154.3% during the third quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after buying an additional 1,874,508 shares during the last quarter. Invesco Ltd. lifted its holdings in Gilead Sciences by 12.0% in the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after buying an additional 1,618,453 shares during the period. Finally, Amundi boosted its stake in Gilead Sciences by 18.2% in the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after acquiring an additional 1,614,355 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $139.71 on Friday. The stock’s fifty day simple moving average is $145.02 and its 200 day simple moving average is $129.21. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $173.41 billion, a PE ratio of 20.64, a PEG ratio of 1.84 and a beta of 0.39. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the previous year, the firm posted $1.90 earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were issued a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. Gilead Sciences’s dividend payout ratio is currently 48.45%.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of analyst reports. Cantor Fitzgerald increased their price target on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Argus lifted their price objective on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Scotiabank upped their price objective on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 11th. Barclays started coverage on Gilead Sciences in a research note on Friday, February 20th. They issued an “equal weight” rating and a $155.00 target price on the stock. Finally, Mizuho boosted their target price on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Twenty-four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $157.62.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the insider owned 131,779 shares in the company, valued at approximately $19,006,485.17. The trade was a 2.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the transaction, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. This trade represents a 1.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 299,280 shares of company stock worth $42,820,550. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.